phone

Osteomyelitis - Pipeline Review, H2 2017

  • Published Date: 08 Aug 2017
  • Number of Pages: 47
  • Category: Healthcare and Medical
  • Country: Global
Osteomyelitis - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Pipeline Review, H2 2017, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.

Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction
Global Markets Direct Report Coverage
Osteomyelitis - Overview
Osteomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Osteomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Osteomyelitis - Companies Involved in Therapeutics Development
Allergan Plc
CrystalGenomics Inc
Debiopharm International SA
Motif Bio Plc
Nabriva Therapeutics AG
Vyome Biosciences Pvt Ltd
Osteomyelitis - Drug Profiles
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CG-400549 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalbavancin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTF-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VCD-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Osteomyelitis - Dormant Projects
Osteomyelitis - Product Development Milestones
Featured News & Press Releases
Dec 13, 2016: Vyome Presents on the Development of the Dual Action Rational Therapeutics Platform at the 2016 ASM Conference on Antibacterial Development
Oct 24, 2016: Allergan to Present New Data on DALVANCE (dalbavancin) at IDWeek 2016 in New Orleans
Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID
Oct 10, 2014: Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Osteomyelitis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Osteomyelitis - Pipeline by Allergan Plc, H2 2017
Osteomyelitis - Pipeline by CrystalGenomics Inc, H2 2017
Osteomyelitis - Pipeline by Debiopharm International SA, H2 2017
Osteomyelitis - Pipeline by Motif Bio Plc, H2 2017
Osteomyelitis - Pipeline by Nabriva Therapeutics AG, H2 2017
Osteomyelitis - Pipeline by Vyome Biosciences Pvt Ltd, H2 2017
Osteomyelitis - Dormant Projects, H2 2017

List Of Figures


Number of Products under Development for Osteomyelitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Osteomyelitis - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Pipeline Review, H2 2017, provides an overview of the Osteomyelitis (Infectious Disease) pipeline

View Report

Osteomyelitis Global Clinical Trials Review, H2, 2014 market research report at USD 2500 and market update available at JSB Market Research.

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports